Medy Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medy-Tox Inc (086900)
Medy-Tox Inc stock price live, this page displays KQ 086900 stock exchange data. View the 086900 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Medy-Tox Inc real time stock price chart below.
What Is the Medy-Tox Inc Stock Price Today?
The Medy-Tox Inc stock price today is 121,000.
What Is the Stock Symbol for Medy-Tox Inc?
The stock symbol for Medy-Tox Inc is ""086900.""
What Stock Exchange Does Medy-Tox Inc Trade On?
Medy-Tox Inc is listed and trades on the KOSDAQ stock exchange.
Is Medy-Tox Inc a Good Stock to Buy?
Determining whether Medy-Tox Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 086900 quote. (ISIN: KR7086900008)
What Is the Medy-Tox Inc Stock Price Today?
The Medy-Tox Inc stock price today is 121,000.
What Is the Stock Symbol for Medy-Tox Inc?
The stock symbol for Medy-Tox Inc is ""086900.""
What Stock Exchange Does Medy-Tox Inc Trade On?
Medy-Tox Inc is listed and trades on the KOSDAQ stock exchange.
Is Medy-Tox Inc a Good Stock to Buy?
Determining whether Medy-Tox Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 086900 quote. (ISIN: KR7086900008)
KOSDAQ
Currency in KRW
121,000
+1,500(+1.26%)
Closed·
Fair Value
An estimate of a Medy-Tox's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118,800
121,000
52 wk Range
112,100
210,500
086900 Scorecard
Full Analysis
Management has been aggressively buying back shares
086900 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Medy-Tox's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118,800121,000
52 wk Range
112,100210,500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.92%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.92%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
086900 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Medy-Tox's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
179,500
Upside
+48.35%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Medy-Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Medy-Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Medy-Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Medy Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Medy-Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Medy-Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Medy-Tox Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Medy-Tox Inc Company Profile
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.
Compare 086900 to Peers and Sector
Metrics to compare | 086900 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship086900PeersSector | |
|---|---|---|---|---|
P/E Ratio | 46.6x | 0.8x | −0.6x | |
PEG Ratio | 0.15 | −0.02 | 0.00 | |
Price/Book | 1.8x | 1.8x | 2.6x | |
Price / LTM Sales | 3.6x | 4.9x | 3.3x | |
Upside (Analyst Target) | 48.8% | 50.3% | 39.0% | |
Fair Value Upside | Unlock | 27.0% | 4.9% | Unlock |
Analyst Ratings
4 Buy
2 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 179,500
(+48.35% Upside)
Earnings
Latest Release
Aug 11, 2025
EPS / Forecast
1,340.00 / 2,705.00
Revenue / Forecast
61.60B / 71.45B
People Also Watch
FAQ
What Stock Exchange Does Medy-Tox Trade On?
Medy-Tox is listed and trades on the KOSDAQ stock exchange.
What Is the Stock Symbol for Medy-Tox?
The stock symbol for Medy-Tox is "086900."
What Is the Medy-Tox Market Cap?
As of today, Medy-Tox market cap is 851.45B.
What Is Medy-Tox's Earnings Per Share (TTM)?
The Medy-Tox EPS (TTM) is 2,832.89.
When Is the Next Medy-Tox Earnings Date?
Medy-Tox will release its next earnings report on 11 Nov 2025.
From a Technical Analysis Perspective, Is 086900 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Medy-Tox Stock Split?
Medy-Tox has split 7 times.
How Many Employees Does Medy-Tox Have?
Medy-Tox has 705 employees.
What is the current trading status of Medy-Tox (086900)?
As of 26 Aug 2025, Medy-Tox (086900) is trading at a price of 121,000.00, with a previous close of 121,000.00. The stock has fluctuated within a day range of 118,800.00 to 121,000.00, while its 52-week range spans from 112,100.00 to 210,500.00.
What Is Medy-Tox (086900) Price Target According to Analysts?
The average 12-month price target for Medy-Tox is KRW179500, with a high estimate of KRW260000 and a low estimate of KRW110000. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +48.35% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.